Literature DB >> 11046088

delta-Opioid receptors are more efficiently coupled to adenylyl cyclase than to L-type Ca(2+) channels in transfected rat pituitary cells.

P L Prather1, L Song, E T Piros, P Y Law, T G Hales.   

Abstract

Opioid receptors often couple to multiple effectors within the same cell. To examine potential mechanisms that contribute to the specificity by which delta-receptors couple to distinct intracellular effectors, we stably transfected rat pituitary GH(3) cells with cDNAs encoding for delta-opioid receptors. In cells transfected with a relatively low delta-receptor density of 0.55 pmol/mg of protein (GH(3)DOR), activation of delta-receptors produced inhibition of adenylyl cyclase activity but was unable to alter L-type Ca(2+) current. In contrast, activation of delta-receptors in a clone that contained a higher density of delta-receptors (2.45 pmol/mg of protein) and was also coexpressed with mu-opioid receptors (GH(3)MORDOR), resulted in not only the expected inhibition of adenylyl cyclase activity but also produced inhibition of L-type Ca(2+) current. The purpose of the present study was to determine whether these observations resulted from differences in delta-opioid receptor density between clones or interaction between delta- and mu-opioid receptors to allow the activation of different G proteins and signaling to Ca(2+) channels. Using the delta-opioid receptor alkylating agent SUPERFIT, reduction of available delta-opioid receptors in GH(3)MORDOR cells to a density similar to that of delta-opioid receptors in the GH(3)DOR clone resulted in abolishment of coupling to Ca(2+) channels, but not to adenylyl cyclase. Furthermore, although significantly greater amounts of all G proteins were activated by delta-opioid receptors in GH(3)MORDOR cells, delta-opioid receptor activation in GH(3)DOR cells resulted in coupling to the identical pattern of G proteins seen in GH(3)MORDOR cells. These findings suggest that different threshold densities of delta-opioid receptors are required to activate critical amounts of G proteins needed to produce coupling to specific effectors and that delta-opioid receptors couple more efficiently to adenylyl cyclase than to L-type Ca(2+) channels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046088

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the δ-Opioid Receptor.

Authors:  Arnaud Proteau-Gagné; Véronique Bournival; Kristina Rochon; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2010-09-17       Impact factor: 4.418

2.  AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Authors:  Kathryn A Seely; Lisa K Brents; Lirit N Franks; Maheswari Rajasekaran; Sarah M Zimmerman; William E Fantegrossi; Paul L Prather
Journal:  Neuropharmacology       Date:  2012-07-04       Impact factor: 5.250

3.  The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.

Authors:  Jennifer L Shoemaker; Kathryn A Seely; Ronald L Reed; John P Crow; Paul L Prather
Journal:  J Neurochem       Date:  2007-01-04       Impact factor: 5.372

4.  Delta receptors are required for full inhibitory coupling of mu-receptors to voltage-dependent Ca(2+) channels in dorsal root ganglion neurons.

Authors:  Wendy Walwyn; Scott John; Matthew Maga; Christopher J Evans; Tim G Hales
Journal:  Mol Pharmacol       Date:  2009-04-08       Impact factor: 4.436

5.  Morphine-induced mu-opioid receptor rapid desensitization is independent of receptor phosphorylation and beta-arrestins.

Authors:  Ji Chu; Hui Zheng; Horace H Loh; Ping-Yee Law
Journal:  Cell Signal       Date:  2008-05-18       Impact factor: 4.315

6.  Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.

Authors:  Parham Gharagozlou; Hasan Demirci; J David Clark; Jelveh Lameh
Journal:  BMC Neurosci       Date:  2002-11-18       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.